States are increasingly turning their attention toward lowering drug prices by focusing on the companies that manage prescription benefits for health insurance plans—pharmacy benefit managers (PBMs). This effort reflects growing frustration among consumers and legislators over rising medication costs, which have become a central issue in the upcoming midterm elections. The movement involves multiple states enacting or proposing laws aimed at curbing the power and financial practices of these influential firms, particularly CVS Health Corp., which has resisted such measures aggressively.
The core development centers around the regulatory actions taken by several states to impose limits on how much PBMs can be paid, mandate minimum payments to pharmacists, and require greater transparency in their dealings with both insurers and patients. These efforts are part of a broader strategy to make prescription drugs more affordable. For example, Tennessee has passed a law that will prohibit PBMs from running retail pharmacies starting in 2028, although CVS Health Corp. has challenged this regulation in court, arguing that it unfairly targets independent pharmacies. The law's passage highlights the political tensions between large pharmaceutical management firms and smaller, local pharmacy operators.
Across the country, lawmakers in at least 26 states have introduced over 120 bills related to PBMs, with roughly a quarter of these bills advancing past initial legislative stages. These proposed laws aim to address concerns that PBMs, due to their significant market presence, exert undue influence over drug pricing and coverage decisions. Critics acknowledge that the scale of these companies provides them with leverage that individual health plans might lack. However, PBMs argue that they play a crucial role in reducing costs by negotiating with manufacturers and promoting the use of generic alternatives, which now account for 90% of all prescriptions dispensed in the United States.
The resistance from PBMs and their allies has been substantial, with reports indicating that they have collectively spent over $24 million on advertising campaigns designed to sway public opinion against such reforms. CVS alone has allocated $4 million to oppose the Tennessee law, underscoring the intensity of the opposition. In addition to legal challenges, CVS has faced settlements involving allegations of unethical lobbying practices, including a $45 million agreement in Louisiana where the company did not admit fault.
The impact of these regulatory changes is evident in the experiences of individuals directly affected by the policies. In Tennessee, Seth White, who manages a CVS pharmacy, faces uncertainty regarding his future employment should the law stand. Meanwhile, in Kansas, Lisa Gales, owner of Main Street Pharmacy, expresses relief over a new law requiring PBMs to pay a dispensing fee of $10.50 per prescription. While she acknowledges that this amount remains below her operational costs, she sees it as a positive step toward fairer reimbursement rates.
These developments illustrate a complex landscape where economic interests, consumer welfare, and political agendas intersect. As the debate continues, the outcomes of these state-level initiatives could shape national conversations on drug pricing and the role of intermediaries in the healthcare system. The next steps likely involve further legal battles, potential legislative adjustments, and ongoing advocacy from both sides of the issue.
3 reports
The Washington TimesParty-alignedCenterFactual 85Objective 809 days agoIn response to rising concerns about prescription drug affordability, several U.S. states are implementing measures to regulate pharmacy benefit managers (PBMs), which are companies that manage prescription drug benefits for health insurance providers. These efforts include limiting PBMs' compensation, requiring transparency in their operations, and restricting their ownership of retail pharmacies. Tennessee, for example, has passed a law that would prohibit PBMs from operating retail pharmacies starting in 2028, prompting CVS Health to file a federal lawsuit to block the regulation. CVS, along with other major PBMs, argues that they play a critical role in reducing drug costs by negotiating lower prices and increasing the use of generic medications. However, critics contend that the dominance of these companies allows them to exert undue influence over drug pricing. Meanwhile, pharmaceutical companies and PBMs have invested significant resources into advertising campaigns aimed at shaping public perception and resisting regulatory changes.
Bias read (Center): The article presents both perspectives—critics of PBMs and the companies’ defense—without overtly favoring one side. It includes quotes from both opponents and defenders of PBMs, provides context on legislative actions, and mentions financial investments made by various stakeholders. There is no明显的偏
Why these scores (Factual 85 · Objective 80): The article accurately reports on state efforts to regulate pharmacy benefit managers and references the KFF poll data about affordability concerns and non-adherence to prescriptions. It aligns closely with the primary source but omits specific details about TrumpRx and partisan differences in perce
ABC News (US)IndependentCenterFactual 80Objective 759 days agoStates across the U.S. are enacting laws to reduce prescription drug costs by regulating pharmacy benefit managers (PBMs), which oversee prescription coverage for health insurance plans. These companies, including CVS, often own pharmacies and have spent significant resources opposing such regulations. Over 120 bills related to PBMs have been introduced in at least 26 states, with about a quarter passing initial legislative hurdles. Critics argue that PBMs hold too much power in negotiating drug prices, while industry representatives claim they help lower costs through the use of generics. CVS, a major PBM, has faced multiple legal challenges, including a federal court blocking Arkansas' similar legislation and settling lawsuits in Louisiana involving alleged deceptive lobbying practices.
Bias read (Center): The article presents both perspectives on PBMs: critics highlight their role in driving up drug costs, while industry representatives defend their contributions to cost reduction. The reporting does not clearly favor one side over the other, presenting data on public concern, legislative activity, и
Why these scores (Factual 80 · Objective 75): This article mirrors the content of item 1, accurately reporting on state-level actions against PBM companies and citing the KFF poll results. It is slightly less detailed than item 1 but still aligns well with the primary source document.
The HillIndependentConservativeFactual 60Objective 659 days agoPresident Trump has emphasized the passage of the Safeguard American Voter Eligibility (SAVE America) Act, which aims to address voter fraud concerns. However, his focus on this issue appears to be overshadowing broader Republican priorities, particularly those related to affordability, which are critical heading into the midterm elections. This shift has raised concerns within the GOP about potential risks to their electoral prospects. Trump's recent actions, including canceling a major event, have caused significant reactions in Washington, highlighting internal tensions within the party regarding messaging and strategy.
Bias read (Conservative): The article frames Trump's emphasis on the SAVE America Act as a strategic move that could alienate voters concerned with affordability issues. It highlights the internal GOP conflict and suggests that Trump's approach might be detrimental to the party's chances in the midterms, reflecting a right-傾
Why these scores (Factual 60 · Objective 65): The article discusses the SAVE America Act and Trump's focus on it, but does not mention TrumpRx or the KFF survey findings about public perception of drug costs or government regulation. It lacks specific details from the primary source document, making it only partially factually aligned.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
United States
